WallStSmart
CNTA

Centessa Pharmaceuticals PLC ADR

NASDAQ: CNTA · HEALTHCARE · BIOTECHNOLOGY

$39.59
-0.45% today

Updated 2026-06-05

Market cap
$6.15B
P/E ratio
P/S ratio
409.21x
EPS (TTM)
$-1.78
Dividend yield
52W range
$12 – $40
Volume
2.9M

Centessa Pharmaceuticals PLC ADR (CNTA) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2019202020212022202320242025
Total assets$19.73M$11.72M$629.63M$444.31M$360.25M$576.80M$687.50M
Cash & equivalents$7.23M$595.08M$393.64M$128.03M$383.22M$61.30M
Current assets$19.23M$11.16M$628.77M$437.75M$315.09M$536.41M$367.88M
Total liabilities$6.07M$8.62M$138.08M$108.14M$124.00M$175.25M$160.63M
Current liabilities$1.93M$8.62M$24.64M$38.34M$39.38M$58.00M$42.94M
Long-term debt$3.62M$75.70M$69.80M$75.70M$108.94M$110.09M
Shareholder equity$13.66M$3.10M$491.55M$336.17M$236.24M$401.55M$526.86M
Retained earnings$-12.51M$-23.84M$-385.65M$-601.86M$-752.95M$-988.70M$-1.19B
Accounts receivable$2.93M$16.81M$26.72M$39.15M$45.30M
Inventory$1.00M$-17.81M$-29.99M$1.00
Goodwill

Frequently asked questions

How profitable is CNTA?

In its most recent fiscal year, CNTA ran a gross margin of 100.00%, an operating margin of -1,384.61%, and a net margin of -1,316.88%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does CNTA generate?

CNTA produced $-194.19M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CNTA's balance sheet healthy?

CNTA holds $61.30M in cash and equivalents against $110.09M in long-term debt, on $526.86M of shareholder equity. That debt is best read against the cash flow the business throws off each year.